The global drug market for migraine treatment is massive and is expected to be worth around SEK 83.7 billion a year within the next five years. Our patented treatment method, Ozilia® Migraine, was CE-marked in May of 2021, more than a year earlier than the initial plan. The Ozilia® treatment for chronic rhinitis is CE-marked since long and under introduction in selected European markets and Saudi Arabia. Our shares are listed in Stockholm on the Nasdaq First North Growth Market with the ticker: CMH.
During treatment, the patient may experience some discomfort in the nose, but aside from that, Ozilia® Migraine. has no other negative side effects.
Ozilia® Migraine can in many cases replace the medication used to treat migraine today. This means that many migraine patients can avoid pills and/or injections.
Ozilia® Migraine treatment is cost effective, resulting also in less sick leave and reduced productivity losses.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.